Oslo, Norway, 10 June 2020: Photocure ASA (OSE:PHO) today announces the
company's first sustainability report, which will be presented at the Annual
General Meeting (AGM) at 17:00 CET. The AGM will be live streamed and Dan
Schneider, President & Chief Executive Officer, will provide a general company
update.

The Photocure Annual General Meeting will be held at Advokatfirmaet Selmer AS'
premises in Tjuvholmen allé 1, 0252 Oslo, Norway on 10 June 2020 at 17:00 CET.
Following the Covid-19 pandemic, shareholders have been encouraged to exercise
their shareholder rights without attending in person through advance voting or
by providing a proxy to the Chairman of the board of directors or the person he
authorizes within 5 June 16:00 CET. The AGM will be live streamed, and questions
can be submitted throughout the event. The AGM will be held in English and can
be followed at:
https://channel.royalcast.com/webcast/hegnarmedia/20200610_4/

Announces sustainability report

"In Photocure, we focus all our efforts and resources on delivering
transformative solutions to improve the lives of bladder cancer patients. We are
proud of our unique technology, making bladder cancer cells glow bright pink,
which to date has helped treat over 500 000 patients worldwide. The primary
growth geographies for Photocure are the U.S. and European markets with large
untapped market opportunities. Our highly regulated business has an economic,
social and environmental impact on our surroundings and stakeholders, most
importantly the positive contribution to the patients' lives, the economies and
the societies in which we operate. Today, we present our first ESG
(Environmental, Social and Governance) report and have set goals for how to
improve our work in the future. I hope this report will provide new insight for
our stakeholders about our response to the sustainability challenges and
opportunities for our business and society," says Dan Schneider, President &
Chief Executive Officer of Photocure.

Guided by the Euronext ESG guidelines and GRI Standards, Photocure has
implemented a process based on stakeholder inclusiveness and materiality to
ensure that Photocure reports on the most material topics for the company and
the industry. During the spring of 2020 Photocure has completed its first
materiality assessment and undertaken systematic stakeholder dialogue, although
simplified due to the effect of Covid-19 on stakeholder groups. The materiality
assessment will ensure that the reporting is aligned with the group's business
objectives, supports the strategy and minimizes risks.

The materiality assessment is focused around key sustainability topics, taking
into account the interests of stakeholders and civil society. They include the
quality and safety of Photocure's products, how they are produced and purchased,
as well as the working environment of its employees. As for the business and
risk minimization, the material topics include ethical conduct in business
relationships, in research and development and when working with personal data.

"For Photocure as a pharmaceutical company, I believe responsibility,
transparency and sustainability must be integrated in our business model and
strategy. For us, efficient, high-quality products produced, sold and used in a
responsible manner is what makes us a successful company, in addition to our
people and culture. Our values constitute key premises for the company, both
internally and externally. Photocure's mission is to deliver transformative
solutions to improve the lives of bladder cancer patients. We seek to do so in a
responsible way and we will continue to do our part to build a better future
based on the foundation of diversity, equality, respect and inclusion,"
Schneider concludes.

Photocure's ESG report for 2019 and the company presentation by Dan Schneider
are enclosed.

For further information, please contact:


Dan Schneider
President and CEO
Photocure ASA
Tel: + 1-609 759-6515
Email: ds@photocure.com

Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email: ed@photocure.no

Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, which makes
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO).  For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com